Nonalcoholic Steatohepatitis Treatment Market

Global Nonalcoholic Steatohepatitis Treatment Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2028: Increasing cases of non-alcoholic steatohepatitis, presence of a healthy product pipeline, obesity and insulin resistance are becoming more common, and rising burden of diabetes are some of the major factors driving the growth of the Global Nonalcoholic Steatohepatitis Treatment Market.

Global Nonalcoholic Steatohepatitis Treatment Market is valued at USD 5.7 Billion in 2022 and expected to reach USD 72.64 Billion by 2029 with CAGR of 43.5% over the forecast period.

Scope-

The syndrome known as non-alcoholic steatohepatitis (NASH) damages the liver in non-drinkers. Patients who have at least one of the risk factors, such as obesity, dyslipidemia, and glucose intolerance, are more likely to acquire it. Although the pathophysiology of NASH is not fully known, it is believed that it is linked to insulin resistance. Blood tests, imaging studies, and occasionally liver biopsies are used to diagnose it. Treatment for NASH include removing the risk factors and contributing factors, such as lowering body fat levels. Cirrhosis, which may result in total liver failure, is thought to be caused in part by NASH.

Due to factors including the lack of authorized medications, the prevalence of the illness, and difficult diagnostic processes, there are significant unmet requirements in the NASH therapy market. Currently, off-label medications like Pioglitazone and Vitamin E dominate the market. These medicines are commonly prescribed all around the world in this field. However, major market players are significantly spending in R&D operations to discover innovative therapies for NASH therapy in order to take advantage of the untapped market potential.

Three key ways that COVID-19 affected the economy include directly impacting medication demand and production, disrupting the flow of goods via distribution networks, and having an economic impact on businesses and financial markets. Many nations, including India, China, Saudi Arabia, Egypt, the United Arab Emirates, and others, are having difficulty moving pharmaceuticals from one location to another as a result of countrywide lockdowns. Due to growing concerns regarding linkages between viral pathobiology and elements of the metabolic syndrome, the COVID-19 pandemic, however, had a favorable effect on the worldwide market for nonalcoholic steatohepatitis treatments.

For instance, the National Center for Biotechnology Information reports that people with COVID-19 infection are more susceptible to underlying metabolic illness, such as hypertension, cardiovascular disease, metabolic syndrome, chronic lung diseases, and type 2 diabetes. Growth of metabolically active fat accompanies the development of chronic inflammatory alterations, insulin resistance, and fat accumulation during metabolic abnormalities, resulting in non-alcoholic fatty liver disease. This resulted in concerns regarding connections between viral pathobiology and metabolic syndrome elements.

The global Nonalcoholic Steatohepatitis Treatment market is segmented based on the drug, end-use, and region & country level. Based on drug, the global Nonalcoholic Steatohepatitis Treatment market is segmented into Obeticholic Acid (OCA), Vitamin E and Pioglitazone, Semaglutide, Lanifibranor, Aramchol, Cenicriviroc, Resmetirom, and Others. By end-use, the global Nonalcoholic Steatohepatitis Treatment market is segmented into hospital pharmacies, retail & specialty pharmacies, and others.

The regions covered in the global Nonalcoholic Steatohepatitis Treatment market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global Nonalcoholic Steatohepatitis Treatment is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players-

Some major key players for the global Nonalcoholic Steatohepatitis Treatment market report cover prominent players like -

• Galmed Pharmaceuticals
• Intercept Pharmaceuticals
• AbbVie Inc.
• Inventiva Pharma
• Madrigal Pharmaceuticals
• Galectin Therapeutics Inc.
• Novo Nordisk A/S
• NGM Biopharmaceuticals Inc
• Gilead Sciences Inc.
• Bristol Myers Squibb
• others.

Segmentation-

By Drug:

• Obeticholic Acid (OCA)
• Vitamin E and Pioglitazone
• Semaglutide
• Lanifibranor
• Aramchol
• Cenicriviroc
• Resmetirom
• Others

By End-Use:

• Hospital Pharmacies
• Retail & Specialty Pharmacies
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Increasing cases of non-alcoholic steatohepatitis, presence of a healthy product pipeline, obesity and insulin resistance are becoming more common, and rising burden of diabetes are some of the major factors driving the growth of the Global Nonalcoholic Steatohepatitis Treatment Market.

NASH is a potentially deadly liver disease that produces severe scarring and cirrhosis. Globally, NAFLD occurs as the most frequent chronic liver condition. NASH is a progressive variant of NAFLD that is progressively replacing NAFLD as the leading cause of end-stage liver transplantation and liver problems. NASH was declared an epidemic on June 12, 2019, according to statistics given by the Global Liver Institute. It now affects about 115 million people, and 357 million individuals are predicted to be afflicted by 2030. Obesity, hyperlipidemia, and type 2 diabetes are major risk factors for NAFLD and NASH; globally, more than 70% of the population is obese, 75% has type 2 diabetes, and 20-80% has hyperlipidemia. If left untreated, NASH may proceed to liver cancer and cirrhosis, necessitating a liver transplant.

According to the American Liver Foundation, NAFLD represents the most prevalent chronic liver disease in the United States. NAFLD is predicted to affect 25% of individuals in the United States, with NASH affecting 20%, or 5% of persons. As per NASH Education Program, NASH incidence is estimated to rise by 63% between 2015 and 2030, and NASH is likely to become the primary factor of liver transplantation in the United States between 2020 and 2025. The American Association for Study of Disease produced a paper in 2018 that forecasted NAFLD disease till 2030 using Markov modeling. According to the research, the prevalence of NAFLD and NASH cases would rise by 21% and 63%, respectively, culminating in 33.5% and 27% prevalence in people.

Despite its rising prevalence, NAFLD/NASH is still an under-recognized disorder, and early identification is crucial to minimizing the risk of progression and the repercussions that come with it. As a result, the nonalcoholic steatohepatitis market is being driven by the increasing incidence of NASH.

Over the projected period, the increasing incidence of insulin resistance and obesity is likely to fuel the nonalcoholic steatohepatitis treatments market development. According to the National Center for Biotechnology Information, type 2 diabetes and obesity, in addition to body overweight, a high fructose diet, metabolic syndrome, and older age, will be key risk factors for NAFLD in May 2022. In clinical examinations, the prognosis of Nonalcoholic Steatohepatitis, Non-alcoholic fatty liver disease (NAFLD), and the more advanced stages of liver diseases, including cirrhosis, is profoundly dependent on the histological outcomes of liver biopsies, whereas, in frequently performed medical examinations, the meaning of NAFLD is usually based on measurement techniques of so-called liver enzymes, such as aspartate amino and alanine aminotransferase (ALT).

One of the primary challenges impeding the development of the global nonalcoholic steatohepatitis treatment market is the lack of FDA-approved precisely customized medications for nonalcoholic steatohepatitis treatment. Despite the tremendous impact on the public health system, there are currently no FDA-approved medications for the treatment of nonalcoholic steatohepatitis. As a result, there is an urgent need for appropriate therapy to address NASH's complicated pathophysiologic processes. Numerous treatments targeting various phases and molecular processes in the disease process are now under development, improving the likelihood of effective NASH therapy in the future.

North America is Expected to Capture a Major Share in the Global Nonalcoholic Steatohepatitis Treatment Market

North America accounts for the majority of the nonalcoholic steatohepatitis market, with the United States leading the way, followed by Canada. With increasing incidences of NASH and favorable government laws supporting the development of diagnostic techniques for this ailment, the nonalcoholic steatohepatitis market in the United States is predicted to rise significantly. With sponsorship from the Allergan Foundation, the American Liver Foundation will join a worldwide community to promote awareness of NASH on International NASH Day, June 12, 2020.

The American Liver Foundation (ALF) is currently testing a NASH Text Messaging Program in which consumers may sign up to get three messages each week for ten weeks. Messages include connections to NASH resources, NASH statistics, interactive quizzes, and practical tips for daily self-management. When the pilot is completed and assessed, ALF will make this technology available to the broader public. It worked with the Global Liver Institute (GLI) on International NASH Day 2020 and posted a few social media postings that included links to GLI articles and the International NASH Day website. Thus, increased activities to raise NASH awareness are propelling the nonalcoholic steatohepatitis market in North America.

News-

Pfizer Received FDA Fast Track Designation for Combination of Ervogastat and Clesacostat for Non-Alcoholic

On May 26, 2022; The FDA approved Pfizer's experimental combination treatment of non-alcoholic steatohepatitis (NASH) with liver cirrhosis, which includes the drugs ervogastat (PF-06865571, DGAT2i), and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor), or a diacylglycerol O-acyltransferase 2 inhibitor. Fast Track is a procedure created to speed up the discovery of new medications and vaccines and to tackle unmet medical needs. It is meant to cure or prevent dangerous illnesses.

Enhanced Liver Fibrosis (ELF) Test Launched by Siemens Healthineers in the U.S.

On January 26, 2022; The Enhanced Liver Fibrosis (ELF) Test was introduced in the US, by Siemens Healthineers. After receiving de novo marketing approval from the US Food and Drug Administration (FDA) in August 2021, this is the first time the test has been made commercially accessible in the nation.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 5.7 Billion
Base year considered	2021
Forecast Period CAGR %:	43.5%
Market Size Expected in 2029:	USD 72.64 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Galmed Pharmaceuticals, Intercept Pharmaceuticals, AbbVie Inc., Inventiva Pharma, Madrigal Pharmaceuticals, Galectin Therapeutics Inc., Novo Nordisk A/S, NGM Biopharmaceuticals Inc, Gilead Sciences Inc., Bristol Myers Squibb, and others.
Segments Covered	By Drug, By End-Use
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa